Regencell Bioscience (RGC) Stock Price, News & Analysis

Company Overview

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Key Stats

• Today's Range: $19.70 to $22.50
• 50-Day Range: $19.99 to $33.72
• 52-Week Range: $9.39 to $83.60
• Volume: 101,743 shs
• Average Volume: 90,685 shs
• Market Capitalization: $9.88 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Regencell Bioscience Stock Analysis - MarketRank™

Regencell Bioscience scored higher than 3% of companies evaluated by MarketBeat, and ranked 84th out of 87 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Regencell Bioscience has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Regencell Bioscience has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Regencell Bioscience has a P/B Ratio of 1,999.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.16% of the float of Regencell Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Regencell Bioscience has a short interest ratio ("days to cover") of 7.15.

Change versus previous month

Short interest in Regencell Bioscience has recently increased by 3.18%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Regencell Bioscience does not currently pay a dividend.

Dividend Growth

Regencell Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.06

News Sentiment

Regencell Bioscience has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Regencell Bioscience this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for RGC on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Regencell Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Regencell Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.00% of the stock of Regencell Bioscience is held by insiders.

Percentage Held by Institutions

0.13% of the stock of Regencell Bioscience is held by institutions.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 6/06/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Medicinal Chemicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RGC
• Previous Symbol: NASDAQ:RGC
• CIK: 1829667
• Web: N/A
• Phone: 852 2155 0823
• Fax: 852-2155-0853
• Employees: 10
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.41
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.01 per share
• Price / Book: 1,999.00

Miscellaneous

• Outstanding Shares: 494,490,000
• Free Float: 484,599,000
• Market Cap: $9.88 billion
• Optionable: N/A
• Beta: 1.65